Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Okrój, Marcin ^a,b   Johansson, Martin ^a   Saxne, Tore ^a   Blom, Anna M ^a   Hesselstrand, Roger ^a  

^a LUND UNIVERSITY   (Sweden)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Biomarkers; Complement; Renal crisis; Scleroderma; Systemic sclerosis

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4D; TERMINAL COMPLEMENT COMPLEX; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; PEPTIDE FRAGMENT;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; FEMALE; GLOMERULUS; HEMOLYSIS; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SCLERODERMA; SCLERODERMA RENAL CRISIS; SYSTEMIC SCLEROSIS; AGED; BLOOD; COMPLEMENT ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; BIOMARKERS; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT C4B; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SCLERODERMA, SYSTEMIC;

EID: 84998775143     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-1168-x     Document Type: Article

References (30)

1. Balbir-Gurman A, Braun-Moscovici Y. Scleroderma - new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol. 2012;26:13-24.
2. Yoshizaki A, Sato S. Abnormal B lymphocyte activation and function in systemic sclerosis. Ann Dermatol. 2015;27:1-9.
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-5.
4. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995;3:39-50.
5. Streicher K, Morehouse CA, Groves CJ, Rajan B, Pilataxi F, Lehmann KP, et al. The plasma cell signature in autoimmune disease. Arthritis Rheumatol. 2014;66:173-84.
6. Chizzolini C, Raschi E, Rezzonico R, Testoni C, Mallone R, Gabrielli A, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum. 2002;46:1602-13.
7. Tedder TF, Poe JC, Fujimoto M, Haas KM, Sato S. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimmun. 2005;8:55-90.
8. Swierczynska Z, Rdultowska H, Blaszczyk M, Jablonska S, Luft S. Circulating immune complexes in systemic scleroderma. Immunol Commun. 1984;13:433-8.
9. Siminovitch K, Klein M, Pruzanski W, Wilkinson S, Lee P, Yoon SJ, et al. Circulating immune complexes in patients with progressive systemic sclerosis. Arthritis Rheum. 1982;25:1174-9.
10. Senaldi G, Lupoli S, Vergani D, Black CM. Activation of the complement system in systemic sclerosis: relationship to clinical severity. Arthritis Rheum. 1989;32:1262-7.
11. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34:J276-86.
12. Blom AM, Osterborg A, Mollnes TE, Okroj M. Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Mol Immunol. 2015;66:164-70.
13. Okroj M, Heinegard D, Holmdahl R, Blom AM. Rheumatoid arthritis and the complement system. Ann Med. 2007;39:517-30.
14. Chimenti MS, Perricone C, Graceffa D, Di Muzio G, Ballanti E, Guarino MD, et al. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol. 2012;30:23-30.
15. McGuigan LE, Geczy AF, Edmonds JP. The immunopathology of ankylosing spondylitis-a review. Semin Arthritis Rheum. 1985;15:81-105.
16. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581-90.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
18. Otteby KE, Holmquist E, Saxne T, Heinegard D, Hesselstrand R, Blom AM. Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis. Arthritis Res Ther. 2013;15:R215.
19. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281-5.
20. Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013;56:232-9.
21. Okroj M, Holmquist E, Sjolander J, Corrales L, Saxne T, Wisniewski HG, et al. Heavy chains of inter alpha inhibitor (IαI) inhibit the human complement system at early stages of the cascade. J Biol Chem. 2012;287:20100-10.
22. Hesselstrand R, Kassner A, Heinegard D, Saxne T. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker. Ann Rheum Dis. 2008;67:1242-8.
23. Happonen KE, Saxne T, Aspberg A, Mörgelin M, Heinegård D, Blom AM. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum. 2010;62:3574-83.
24. Batal I, Domsic RT, Shafer A, Medsger Jr TA, Kiss LP, Randhawa P, et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol. 2009;40:332-40.
25. Denton CP, Lapadula G, Mouthon L, Müller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford). 2009;48 Suppl 3:iii32-5.
26. Steen VD, Costantino JP, Shapiro AP, Medsger Jr TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113:352-7.
27. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100:485-94.
28. Hesselstrand R, Scheja A, Wuttge DM. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol. 2012;41:39-43.
29. Sturfelt G, Truedsson L. Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol. 2012;8:458-68.
30. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol. 1998;37:15-20.